The Food and Drug Administration requested no additional clinical
studies from Repros Therapeutics Inc. (Nasdaq: RPRX) for its New Drug
Application for Androxal. The stock price leaped $3.67 to close at $10.12.
No additional studies for Repros Therapeutics
November 07, 2014 at 18:16 PM EST
